ライフサイエンスコーパス: human papillomavirus

1 ng against human papillomavirus and low-risk human papillomavirus.

2 proteins in 3D with a case study focused on human papillomavirus.

3 maviruses BK/JC/MCV, human adenoviruses, and human papillomaviruses.

4 sed to detect viral nucleic acids, including human papillomavirus 16 (HPV-16) and parvovirus B19 (PB-

5 and wildtype p53 (p53WT) inactivated by the human papillomavirus 16 (HPV16) E6 oncogene.

6 Human papillomavirus 16 (HPV16) E7 has long been known t

7 Infectious human papillomavirus 16 (HPV16) L1/L2 pseudovirions were

8 eatment, dramatically decreased infection of human papillomavirus 16 (HPV16) pseudovirus (PsV).

9 s, including bovine papillomavirus (BPV) and human papillomavirus 16 (HPV16), associate with the cell

10 confirm a much higher incidence of high-risk human papillomavirus 16 (HPV16)-mediated carcinogenesis

11 e loss of E2 host gene regulation.IMPORTANCE Human papillomavirus 16 (HPV16)-positive tumors that ret

12 rogression.IMPORTANCE Although the high-risk human papillomavirus 16 infects anogenital and oropharyn

13 iority 1 month after the last dose of 2-dose human papillomavirus 16/18 AS04-adjuvanted (AS04-HPV-16/

14 Human papillomaviruses 16 (HPV16) is the primary causati

15 Human papillomavirus-16 and HPV-18 incidence were simila

16 Human papillomavirus-16 cleared significantly slower tha

17 Human papillomavirus-16 incidence was higher among high-

18 n Australia, high uptake of the quadrivalent human papillomavirus (4vHPV) vaccine has led to reductio

19 Human papillomavirus 58 (HPV58) is found in 10 to 18% of

20 uitment to the replication origin.IMPORTANCE Human papillomaviruses affect an estimated 75% of the se

21 tion of tumor-bearing mice with R-DOTAP plus human papillomavirus Ags induces complete regression of

22 itudinal data on the E6/E7 mRNA-based Aptima human papillomavirus (AHPV) assay exceeding three years

23 cell carcinoma (SCC) is associated with both human papillomavirus and HIV infection.

24 und for male circumcision protecting against human papillomavirus and low-risk human papillomavirus.

25 CC with known p16 tumor status (surrogate of human papillomavirus) and cigarette smoking history (pac

26 the pTEFb binding domain of Brd4.IMPORTANCE Human papillomaviruses are the major causative agents of

27 The recognition of tobacco, alcohol, and human papillomavirus as etiological agents in oral and h

28 r T cell responses in complete regression of human papillomavirus-associated metastatic cervical canc

29 radiotherapy (RT) for selected patients with human papillomavirus-associated oropharyngeal squamous c

30 ose cisplatin are favorable in patients with human papillomavirus-associated oropharyngeal squamous c

31 burden and frequency of infection declined, human papillomavirus-associated oropharyngeal squamous-c

32 In the human papillomavirus-associated TC-1 model, vaccination

33 the skin-which has been associated with beta human papillomavirus (beta-HPV) infection-is increased b

34 Beta genus human papillomaviruses (beta-HPVs) cause cutaneous squam

35 evaluated the association between beta genus human papillomaviruses (betaPV) and keratinocyte carcino

36 Findings from previous studies of cutaneous human papillomavirus (cuHPV) infection and keratinocyte

37 Plasma circulating tumor human papillomavirus DNA (ctHPVDNA) is a sensitive and s

38 Tobacco- or human papillomavirus- driven oropharyngeal squamous cell

39 growth and prolong survival in melanoma and human papillomavirus E7 in vivo tumor models.

40 ted HSV type 2, influenza hemagglutinin, and human papillomavirus E7 protein.

41 Human papillomavirus genotype-specific concordance is mo

42 Human papillomavirus genotyping is important to study na

43 evel utterance interaction for communicating human papillomavirus health information.

44 ning of all HIV-infected women regardless of human papillomavirus history or sexual practices.

45 a, Dengue, SARS-Cov-2 (inducer of COVID-19), human papillomavirus, HIV, etc.) viruses and diagnosis o

46 system was utilized to quantitatively detect human papillomavirus (HPV) 16 and 18 DNAs with sensitivi

47 Human papillomavirus (HPV) 16 displays substantial seque

48 evalence of anal squamous abnormalities, and human papillomavirus (HPV) 16.

49 Natural variants of human papillomavirus (HPV) are classified into lineages

50 Head and neck cancers positive for human papillomavirus (HPV) are exquisitely radiosensitiv

51 ital epithelium that are associated with the human papillomavirus (HPV) are far more readily cured wi

52 cibility and performance of the BD Onclarity human papillomavirus (HPV) assay (Onclarity) on the BD V

53 The human papillomavirus (HPV) capsid comprises two viral pr

54 ithin the endosome triggers uncoating of the human papillomavirus (HPV) capsid, whereupon host cyclop

55 Human papillomavirus (HPV) causes an increasing proporti

56 -CoV), Mycobacterium tuberculosis (MTB), and human papillomavirus (HPV) DNA based on a colorimetric p

57 Methylation of the human papillomavirus (HPV) DNA has been proposed as a no

58 Detection of human papillomavirus (HPV) DNA in genital samples may no

59 The human papillomavirus (HPV) E2 protein is a key regulator

60 Human papillomavirus (HPV) E2 proteins are integral for

61 GX-188E vaccination has been shown to induce human papillomavirus (HPV) E6-specific and E7-specific T

62 The human papillomavirus (HPV) E7 oncoprotein is a primary d

63 High-risk human papillomavirus (HPV) E7 proteins enable oncogenic

64 Swabs were human papillomavirus (HPV) genotyped, and the type-speci

65 e has led to reductions in the prevalence of human papillomavirus (HPV) genotypes 6, 11, 16, and 18 i

66 infections (STIs)-including a large panel of human papillomavirus (HPV) genotypes-and high-grade anal

67 We have developed a new human papillomavirus (HPV) genotyping assay for detectio

68 Baseline pyrosequencing methylation and human papillomavirus (HPV) genotyping assays were perfor

69 Australia instituted funded female human papillomavirus (HPV) immunization in 2007, followe

70 ly representative prevalence data on genital human papillomavirus (HPV) in males in the United States

71 Cutaneous beta human papillomavirus (HPV) infection across cutaneous an

72 l (0.84, 0.75-0.95; k=5; I(2)=0%) and penile human papillomavirus (HPV) infection among HIV-infected

73 Limited data are available on human papillomavirus (HPV) infection among human immunod

74 ne responses is critical for both persistent human papillomavirus (HPV) infection and associated canc

75 obiota (VM) may influence risk of persistent Human Papillomavirus (HPV) infection and cervical carcin

76 al cancer screening results-namely high-risk human papillomavirus (HPV) infection and cytohistopathol

77 spective data on the natural history of anal human papillomavirus (HPV) infection are scarce in human

78 Human papillomavirus (HPV) infection correlates with hig

79 Human papillomavirus (HPV) infection distinctly alters m

80 Human Papillomavirus (HPV) infection has been recognized

81 Whether type-specific human papillomavirus (HPV) infection influences the risk

82 Human Papillomavirus (HPV) infection involves multiple s

83 High-risk human papillomavirus (HPV) infection is one of the first

84 High-risk anal human papillomavirus (HPV) infection is prevalent among

85 The knowledge that persistent human papillomavirus (HPV) infection is the main cause o

86 Persistent human papillomavirus (HPV) infection is the vital factor

87 es provide evidence of the harmful effect of human papillomavirus (HPV) infection on pregnancy, but o

88 en the vaginal microbiota (VMB) composition, human papillomavirus (HPV) infection, and cervical intra

89 Human papillomavirus (HPV) infection, and its sequelae o

90 n uninfected youth for persistent anogenital human papillomavirus (HPV) infection, due to prolonged i

91 n uninfected youth for persistent anogenital human papillomavirus (HPV) infection, due to prolonged i

92 Anal human papillomavirus (HPV) infection, most notably HPV16

93 In human papillomavirus (HPV) infection, the cellular prote

94 thological abnormalities resembling those of human papillomavirus (HPV) infection.

95 Although new human papillomavirus (HPV) infections can occur at all a

96 Oncogenic human papillomavirus (HPV) infections cause most cases o

97 tion.IMPORTANCE The persistence of high-risk human papillomavirus (HPV) infections is the key risk fa

98 WH) are more likely to smoke and harbor oral human papillomavirus (HPV) infections, putting them at h

99 e, we uncover a novel mechanism by which the human papillomavirus (HPV) inhibits the activity of CBI

100 We conducted a critical review of human papillomavirus (HPV) integration into the host gen

101 Human papillomavirus (HPV) is a common sexually transmit

102 Human papillomavirus (HPV) is a common sexually transmit

103 Human papillomavirus (HPV) is a necessary but insufficie

104 Persistent infection with high-risk human papillomavirus (HPV) is a prerequisite for the dev

105 Human papillomavirus (HPV) is one of the most common sex

106 -relevant oncogenic HPV genotypes.IMPORTANCE Human papillomavirus (HPV) is the causative agent of cer

107 Human papillomavirus (HPV) is the causative agent of cer

108 Human papillomavirus (HPV) L1 and L2 capsid proteins sel

109 cularly those in immunocompromised patients, human papillomavirus (HPV) may be an important factor.

110 infection and complete the viral life cycle, human papillomavirus (HPV) needs to alter the transcript

111 on of critical cell cycle checkpoints by the human papillomavirus (HPV) oncoprotein E7 results in rep

112 The human papillomavirus (HPV) plays a central role in cervi

113 Oncoprotein E6 of high-risk human papillomavirus (HPV) plays a critical role in indu

114 We assessed human papillomavirus (HPV) prevalence among HPV-16/18-va

115 Differences in oral human papillomavirus (HPV) prevalence and contrasts in H

116 To estimate changes in oral human papillomavirus (HPV) prevalence attributable to va

117 The human papillomavirus (HPV) rate of evolution is essentia

118 (F-M) transmission of genital infection with human papillomavirus (HPV) relative to male-to-female (M

119 The human papillomavirus (HPV) replication cycle is tightly

120 cervical cancer in England, UK, will change: human papillomavirus (HPV) screening will be the primary

121 Differences in human papillomavirus (HPV) seroprevalence by sex have be

122 s sarcoma-associated herpesvirus (KSHV), and human papillomavirus (HPV) share the common property of

123 Pathology-based measures of human papillomavirus (HPV) status are routinely obtained

124 of EXO miRNAs associated with cancer type or human papillomavirus (HPV) status, suggesting their pote

125 rammed death ligand 1 (PD-L1) expression and human papillomavirus (HPV) status.

126 ource settings, but quite low specificity of human papillomavirus (HPV) testing, particularly in wome

127 nd compared it with post-treatment high-risk human papillomavirus (HPV) testing.

128 Inexpensive and easy-to-perform human papillomavirus (HPV) tests are needed for primary

129 We used a transmission dynamic model of human papillomavirus (HPV) to investigate the effect of

130 e influence on biopsy and treatment rates of human papillomavirus (HPV) triage of cytology showing at

131 al cancer incidence is rapidly rising due to human papillomavirus (HPV) type 16 infection.

132 int was treatment success, defined as either human papillomavirus (HPV) type-specific clearance among

133 8, Scotland launched routine vaccination for human papillomavirus (HPV) types 16 and 18, targeted at

134 s-reactive immunogenicity against nonvaccine human papillomavirus (HPV) types 31 and 45 following 2 d

135 oximately 90% of genital warts are caused by human papillomavirus (HPV) types 6 and 11.

136 ta on the relative carcinogenic potential of human papillomavirus (HPV) types among women infected wi

137 Specimens were tested for 37 human papillomavirus (HPV) types and for FAM19A4 and mic

138 Human papillomavirus (HPV) types differ by geographic lo

139 cribe the rate of subsequent GWs, associated human papillomavirus (HPV) types, and time to subsequent

140 We designed a universal human papillomavirus (HPV) typing assay based on target

141 inform global efforts, we modelled potential human papillomavirus (HPV) vaccination and cervical scre

142 Efforts are being made to scale up human papillomavirus (HPV) vaccination for adolescent gi

143 Human papillomavirus (HPV) vaccination has been associat

144 A reduced, 2-dose schedule of human papillomavirus (HPV) vaccination has been endorsed

145 In the United States, human papillomavirus (HPV) vaccination has been recommen

146 Cervical screening and human papillomavirus (HPV) vaccination have been impleme

147 Bhutan implemented a national program for human papillomavirus (HPV) vaccination in 2010 involving

148 the health impact and cost-effectiveness of human papillomavirus (HPV) vaccination in girls.

149 In the United States, the routine age for human papillomavirus (HPV) vaccination is 11 to 12 years

150 Human papillomavirus (HPV) vaccination is safe and effic

151 Human papillomavirus (HPV) vaccination is still not reac

152 Human papillomavirus (HPV) vaccination is suboptimally u

153 Increasing evidence suggests that 1-dose human papillomavirus (HPV) vaccination may protect signi

154 Human papillomavirus (HPV) vaccination of girls with ver

155 ral countries have implemented a 2-dose (2D) human papillomavirus (HPV) vaccination schedule for adol

156 he duration of immunity induced by different human papillomavirus (HPV) vaccination schedules and the

157 ntervention coverage targets for scale-up of human papillomavirus (HPV) vaccination to 90%, twice-lif

158 More than 10 years have elapsed since human papillomavirus (HPV) vaccination was implemented.

159 Before 2016, human papillomavirus (HPV) vaccination was recommended i

160 Before 2016, human papillomavirus (HPV) vaccination was recommended o

161 -term demand for treatment in the context of human papillomavirus (HPV) vaccination.

162 ion reported across AS04-adjuvanted bivalent human papillomavirus (HPV) vaccine (2vHPV) studies, we r

163 Uptake of human papillomavirus (HPV) vaccine among girls in the Du

164 ation of antibody response following reduced human papillomavirus (HPV) vaccine doses has not been de

165 To understand real-world human papillomavirus (HPV) vaccine impact, continuous ev

166 ficacy and effectiveness of the quadrivalent human papillomavirus (HPV) vaccine in preventing high-gr

167 The bivalent human papillomavirus (HPV) vaccine is highly effective a

168 The quadrivalent human papillomavirus (HPV) vaccine is recommended for al

169 Despite an efficacious prophylactic human papillomavirus (HPV) vaccine there is still a cons

170 carcinoma in situ (CIN2+) during a period of human papillomavirus (HPV) vaccine uptake and changing c

171 Human papillomavirus (HPV) vaccine was recommended in 20

172 e vaccination with the prophylactic bivalent human papillomavirus (HPV) vaccine.

173 Human papillomavirus (HPV) vaccines are indicated for an

174 tly no available PM vaccine and the marketed Human Papillomavirus (HPV) vaccines are prohibitively ex

175 Highly effective human papillomavirus (HPV) vaccines are used in many nat

176 We studied the association between human papillomavirus (HPV) viral load (VL) and HPV conco

177 nal integrations of hepatitis B virus (HBV), human papillomavirus (HPV), Epstein-Barr virus (EBV), an

178 d the first national study in Togo to assess human papillomavirus (HPV), HIV, and other sexually tran

179 re increasingly attributed to infection with human papillomavirus (HPV), primarily HPV-16.

180 The high prevalence of human papillomavirus (HPV), the most common sexually tra

181 or morbidities related to infection with the human papillomavirus (HPV), yet their HPV vaccine initia

182 Cellular immunotherapeutics targeting the human papillomavirus (HPV)-16 E6 and E7 proteins have ac

183 control group, GUWE treated DCs pulsed with human papillomavirus (HPV)-16 E6/E7 peptides significant

184 nodeficiency virus (HIV) are at high risk of human papillomavirus (HPV)-associated cancers.

185 ole in the proteasomal degradation of p53 in human papillomavirus (HPV)-associated cancers.

186 Trends in human papillomavirus (HPV)-associated cervical lesions c

187 cell therapy for the treatment of metastatic human papillomavirus (HPV)-associated epithelial cancers

188 The survival disparity was confined to human papillomavirus (HPV)-associated oropharyngeal canc

189 s (EBV) is implicated in the pathogenesis of human papillomavirus (HPV)-associated oropharyngeal squa

190 NA) is a sensitive and specific biomarker of human papillomavirus (HPV)-associated oropharyngeal squa

191 However, the role of gammadelta T cells in human papillomavirus (HPV)-associated uterine cervical S

192 ndrome and in a variety of cancers including human papillomavirus (HPV)-caused cervical cancer.

193 We detected human papillomavirus (HPV)-clade-specific differences in

194 s of natural lesions, organotypic rafts, and human papillomavirus (HPV)-immortalized keratinocytes ar

195 HIV enhances human papillomavirus (HPV)-induced carcinogenesis.

196 ion levels were significantly upregulated in human papillomavirus (HPV)-infected cell lines and tissu

197 Human papillomavirus (HPV)-negative head and neck squamo

198 Human papillomavirus (HPV)-negative oropharyngeal squamo

199 ation of a homozygous ITK mutation with beta-human papillomavirus (HPV)-positive epidermodysplasia ve

200 Human papillomavirus (HPV)-positive head and neck squamo

201 Patients with human papillomavirus (HPV)-positive head and neck squamo

202 The incidence of human papillomavirus (HPV)-positive oropharyngeal cancer

203 Patients with human papillomavirus (HPV)-positive oropharyngeal squamo

204 The burden of human papillomavirus (HPV)-positive oropharyngeal squamo

205 Compared to primary human papillomavirus (HPV)-positive tumors, many recurre

206 Human papillomavirus (HPV)-related biomarkers have shown

207 experienced an increase in the incidence of human papillomavirus (HPV)-related cancers that are not

208 m of this study was to determine the risk of human papillomavirus (HPV)-related carcinomas and premal

209 urpose Cancer survivors are at high risk for human papillomavirus (HPV)-related morbidities; we estim

210 Here we show that human papillomavirus (HPV)-specific B cell responses are

211 ol (AJCC/UICC) staging system, developed for human papillomavirus (HPV)-unrelated disease, discrimina

212 nearly epidemic rate, largely driven by the human papillomavirus (HPV).

213 pillomatosis is a benign condition caused by human papillomavirus (HPV).

214 kinase 4 and 6 (CDK4/6), rather than by the human papillomavirus (HPV).

215 rare malignancy associated with infection by human papillomavirus (HPV).

216 l carcinogens or malignant transformation by human papillomavirus (HPV).

217 st been largely associated with tobacco use, human papillomavirus (HPV+) oropharynx cancer has in rec

218 Oncogenic human papillomaviruses (HPV) are small DNA viruses that

219 High-risk human papillomaviruses (HPV) are the causative agents of

220 Human papillomaviruses (HPV) cause over 500 000 cervical

221 Human papillomaviruses (HPV) replicate their genomes in

222 aused by vaccine-preventable infections with human papillomaviruses (HPV).

223 in cancers are associated with infections by human papillomaviruses (HPV).

224 The study accrued 59 patients (human papillomavirus [HPV] positive, n = 34; HPV negativ

225 Notably, glycopolymers efficiently inhibit Human Papillomavirus (HPV16) infection in vitro and main

226 ed digital LAMP on a sp-SlipChip to quantify human papillomaviruses (HPVs) 16 and 18 and tested this

227 Infections with high-risk human papillomaviruses (HPVs) are a major cause of anoge

228 Human papillomaviruses (HPVs) are a significant public h

229 Antibodies against human papillomaviruses (HPVs) are biomarkers for current

230 Human papillomaviruses (HPVs) are causative agents in an

231 Oncogenic human papillomaviruses (HPVs) are closely linked to majo

232 initiation of viral DNA synthesis.IMPORTANCE Human papillomaviruses (HPVs) are highly infectious path

233 Infection caused by high-risk human papillomaviruses (HPVs) are implicated in the aeti

234 Human papillomaviruses (HPVs) are the most common sexual

235 beta-Human papillomaviruses (HPVs) cause near ubiquitous late

236 High-risk human papillomaviruses (HPVs) constitutively activate at

237 We report that oncogenic human papillomaviruses (HPVs) generate circRNAs, some of

238 Infection by human papillomaviruses (HPVs) has been implicated in the

239 own about the epidemiology of beta and gamma human papillomaviruses (HPVs) in oral cavities of health

240 Human papillomaviruses (HPVs) infect keratinocytes of st

241 Human papillomaviruses (HPVs) infect squamous epithelia

242 The E6 protein of both mucosal high-risk human papillomaviruses (HPVs) such as HPV-16, which have

243 To replicate, the human papillomaviruses (HPVs) that cause anogenital and

244 lthough many high-risk mucosal and cutaneous human papillomaviruses (HPVs) theoretically have the pot

245 Two common human papillomaviruses (HPVs), HPV-6 and -11, are implic

246 Persistent infection by specific oncogenic human papillomaviruses (HPVs), including HPV58, has been

247 Evidence suggests that beta human papillomaviruses (HPVs), together with ultraviolet

248 k of many cancers, including those caused by human papillomaviruses (HPVs).

249 The risk of anal cancer due to high-risk human papillomavirus (HR-HPV) is higher in women living

250 l liquid-based cytology (aLBC) and high-risk human papillomavirus (HR-HPV) testing to predict histolo

251 High-risk human papillomaviruses (HR-HPVs) promote cervical cancer

252 High-risk human papillomavirus (hrHPV) causes cervical cancer.

253 xamined the trend in prevalence of high-risk human papillomavirus (hrHPV) cervical infection among Rw

254 play a role in modulating risk of high-risk human papillomavirus (hrHPV) infection.

255 he incidence and clearance of anal high-risk human papillomavirus (hrHPV) infections and determinants

256 ss the diagnostic test accuracy of high-risk human papillomavirus (hrHPV) testing of self-collected u

257 High-risk human papillomavirus (hrHPV) testing to triage women wit

258 PV-related disease.IMPORTANCE High-risk-type human papillomaviruses (hrHPVs) cause 5% of all cancer c

259 gnized, for example, Helicobacter pylori and human papillomavirus in the cases of gastric non-cardia

260 ated functions, such as a potential role for human papillomavirus-induced chromosomal alterations in

261 betes, high total cholesterol, hypertension, human papillomavirus infection and related pre-cancerous

262 al and experimental data implicate cutaneous human papillomavirus infection as co-factor in the devel

263 on; 33.9% (95% CI: 24.3-43.5%) for high-risk human papillomavirus infection from cervical samples and

264 ra of widespread testing for the presence of human papillomavirus infection in patients with HNSCC.

265 betes, high total cholesterol, hypertension, human papillomavirus infection, and related precancerous

266 counseled to recognize the signs of genital human papillomavirus infection.

267 oss of immunoregulatory control of oncogenic human papillomavirus infection.

268 sed genome integration.IMPORTANCE Persistent human papillomavirus infections can cause a variety of s

269 Human papillomavirus may also be associated with intraut

270 status were enrolled, patients known to have human papillomavirus-negative tumors were ineligible.

271 sexually transmitted infections and to treat human papillomavirus neoplasia.

272 mpact of vaccinating girls and women against human papillomavirus on HPV infections, anogenital wart

273 Human papillomavirus-positive oropharynx cancer incidenc

274 positron emission tomography in mice bearing human papillomavirus-positive tumors, as well as influen

275 Human papillomavirus prevalence and determinants of geno

276 The detection of known human papillomaviruses (PVs) from targeted wet-lab appro

277 protocols on patient-derived xenografts from human papillomavirus-related (HPV(+)) head and neck squa

278 C was also associated with increased risk of human papillomavirus-related cancers, including anal can

279 Using human papillomavirus-related oropharyngeal carcinoma as

280 As an example, we applied our pipeline to human papillomavirus-related oropharyngeal squamous cell

281 f inflammatory skin diseases and in limiting human papillomavirus replication in human keratinocytes.

282 ded with the appropriate peptides, we imaged human papillomavirus-specific CD8(+) T cells by positron

283 Although patients with unknown human papillomavirus status were enrolled, patients know

284 multivariable analysis adjusting for stage, human papillomavirus status, and smoking history.

285 were randomly assigned (1:1), stratified by human papillomavirus status, to nivolumab (3 mg/kg intra

286 Human papillomavirus testing led to faster and more comp

287 Human papillomavirus transgenic mice bearing CIN lesions

288 In human papillomavirus transgenic mice engineered to expre

289 , the preventive effect of MPA was absent in human papillomavirus transgenic mice in which the expres

290 In a human papillomavirus tumor model system, a single s.c. i

291 Several human papillomavirus type 16 (HPV16) oncoproteins contri

292 avirus transgenic mice engineered to express human papillomavirus type 16 E6 and E7, short-term treat

293 al CD8(+) T cell responses against high-risk human papillomavirus type 16 E7 oncoprotein and conferre

294 proteins, such as the oncogene protein E7 of human papillomavirus type 16, which contain both ordered

295 Human papillomavirus types were stratified as vaccine ty

296 ormation Dialogue Ontology for patient-level human papillomavirus vaccine counseling and potentially

297 he United States and parts of the world, the human papillomavirus vaccine uptake is below the prescri

298 e-induced autoimmune diseases; (5) safety of human papillomavirus vaccine; (6) aluminum adjuvant-indu

299 ANCE After internalization, the nonenveloped human papillomavirus virion uncoats in the endosome, whe

300 Human papillomavirus was significantly associated with p